HALF YEAR REPORT ON LIQUIDITY CONTRACT

27 Jul 2017 10:57 CEST

ANNUAL REPORT ON THE LIQUIDITY CONTRACT 

Paris and Boston, July 27, 2017 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of June 30, 2017:

-        131,934 shares

-         € 390,277.09

For the prior (December 31, 2016), the corresponding figures were:

-        394 422 shares

-        €134 790,14

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com

LIFESCI ADVISORS- Investor Relations / Financial Communications

Chris Maggos

+41 79 367 6254

chris@lifesciadvisors.com

Connect_neovacs_regulated-_information_liquidity_contract_juin_2017.pdf